Managing Asthma Patients with AMAZE™: A Novel Disease Management Platform
Study identifier:N4280000000
ClinicalTrials.gov identifier:NCT04868500
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Managing Asthma Patients with AMAZE™: A Novel Disease Management Platform, A Clinical Pilot Study
Medical condition
asthma
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
49
Study type
Interventional
Age
18 Years - n/a
Date
Study Start Date: 27 Apr 2021
Primary Completion Date: 30 Nov 2021
Study Completion Date: 30 Nov 2021
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Health Services Research
Verification:
Verified 01 Jan 2023 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Massachusetts General Hospital, Evidera
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Massachusetts General Hospital (MGH) Participants Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months. | Device: AMAZE™ Application Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months. |
| Experimental: Massachusetts General Hospital (MGH) Clinical Site Staff Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting. | Device: AMAZE™ Dashboard Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting. |
